PT  - JOURNAL ARTICLE
AU  - Zhou, Jingyu
AU  - Yan, Yi
AU  - Guo, Lei
AU  - Ou, Huiying
AU  - Hai, Jian
AU  - Zhang, Chaojie
AU  - Wu, Zhaoyun
AU  - Tang, Lili
TI  - Distinct outcomes in patients with different molecular subtypes of inflammatory breast cancer
DP  - 2014 Nov 01
TA  - Saudi Medical Journal
PG  - 1324--1330
VI  - 35
IP  - 11
4099  - http://smj.org.sa/content/35/11/1324.short
4100  - http://smj.org.sa/content/35/11/1324.full
SO  - Saudi Med J2014 Nov 01; 35
AB  - OBJECTIVES: To determine the outcome of patients with luminal A, luminal B, human epidermal growth factor receptor-2 (HER-2) positive, and triple negative molecular subtypes of inflammatory breast cancer (IBC) using a retrospective analysis.METHODS: This study was conducted between February 2004 and February 2010 in 3 different hospitals in China. The clinical outcomes, pathological features, and treatment strategies were analyzed in 67 cases of IBC without distant metastases. A chi-square test and one-way ANOVA were used to assess outcomes between different subtypes. Overall survival (OS) was analyzed using the Kaplan-Meier method and multivariate analysis was conducted using the Cox regression model.RESULTS: The 2-year OS rate was 55% for the entire cohort. Median OS time among patients with luminal A was 35 months, luminal B was 30 months, HER-2 positive was 24 months, and triple negative subtypes was 20 months, and were significantly different from each other (p=0.001). Using multivariate analysis, luminal A had 76% (p=0.037), luminal B had 54% (p=0.048), and HER-2 positive subtypes had 47% (p=0.032) decreased risk of death compared with the triple negative subtype. Furthermore, elevated Ki-67 labeling was associated with increased risk of death, while the surgical treatment significantly improved patient survival.CONCLUSION: Breast cancer subtypes are associated with distinct outcomes in IBC patients. Patients that presented with triple negative IBC had poorer outcome than luminal A, luminal B, and HER-2 subtypes. These results indicate that IBC is a heterogeneous disease similar to the conventional breast cancer.